Q-omics provides the consensus-scored ZNF610 profile across patient tissues and cancer cell-line models. ZNF610 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, ZNF610 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZNF610 RNA expression shows 19,732 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, KIRC, and THYM as cancer lineages where ZNF610 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF610 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF610 survival associations across molecular data types. ZNF610 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF610 RNA expression–survival associations across cancer types. High ZNF610 expression shows unfavorable associations in LUSC, SCLC and READ, but favorable associations in KIRC, UVM and ACC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for ZNF610 RNA expression.
This table summarizes ZNF610 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF610. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF610 shows lower tumor expression in KIRC and KICH and higher tumor expression in BRCA, CHOL, BLCA and LIHC. The KIRC box plot shows higher ZNF610 RNA expression in normal versus tumor tissue (log2 FC = −0.552, t-test p < 0.001).
This table shows molecular features associated with ZNF610 in patient tissues and cancer cell lines. In patient samples, ZNF610 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF610 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
